These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21097448)

  • 21. Brucellosis of the spine affecting multiple non-contiguous levels.
    Charalambides C; Papademetriou K; Sgouros S; Sakas D
    Br J Neurosurg; 2010 Oct; 24(5):589-91. PubMed ID: 20707678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.
    McGonagle D; Tan AL; Shankaranarayana S; Madden J; Emery P; McDermott MF
    Ann Rheum Dis; 2007 Dec; 66(12):1683-4. PubMed ID: 17998217
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome.
    Kluger N; Rivière S; Guillot B; Bessis D
    Acta Derm Venereol; 2008; 88(3):287-8. PubMed ID: 18480937
    [No Abstract]   [Full Text] [Related]  

  • 24. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.
    Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC
    Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Discitis in a pediatric patient].
    Mäkelä M; Rikalainen H; Mertsola J; Ruuskanen O
    Duodecim; 1996; 112(18):1661-4. PubMed ID: 10596160
    [No Abstract]   [Full Text] [Related]  

  • 26. Tophaceous gout of the lumbar spine.
    Ko KH; Huang GS; Chang WC
    J Clin Rheumatol; 2010 Jun; 16(4):200. PubMed ID: 20511985
    [No Abstract]   [Full Text] [Related]  

  • 27. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.
    Galeotti C; Tran TA; Franchi-Abella S; Fabre M; Pariente D; Koné-Paut I
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):920-4. PubMed ID: 19131781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.
    Brenner M; Ruzicka T; Plewig G; Thomas P; Herzer P
    Br J Dermatol; 2009 Nov; 161(5):1199-201. PubMed ID: 19673875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.
    Mitroulis I; Papadopoulos VP; Konstantinidis T; Ritis K
    Neth J Med; 2008 Dec; 66(11):489-91. PubMed ID: 19075317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diskitis in toddlers revisited.
    Haidar R; Muwakkit SA; Saad S; Dbaibo GS
    Clin Pediatr (Phila); 2010 Mar; 49(3):290-2. PubMed ID: 20164074
    [No Abstract]   [Full Text] [Related]  

  • 31. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
    Swart JF; Barug D; Möhlmann M; Wulffraat NM
    Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment.
    Benucci M; Damiani A; Arena A; Infantino M; Manfredi M; Li Gobbi F
    Reumatismo; 2016 Dec; 68(3):163-165. PubMed ID: 27981820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case 7: differential diagnosis of advanced gout.
    Edwards NL
    Am J Med; 2006 Nov; 119(11 Suppl 1):S23-4. PubMed ID: 17059909
    [No Abstract]   [Full Text] [Related]  

  • 34. Remission of Schnitzler syndrome after treatment with anakinra.
    Frischmeyer-Guerrerio PA; Rachamalla R; Saini SS
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):617-9. PubMed ID: 18592830
    [No Abstract]   [Full Text] [Related]  

  • 35. The modern management of gout.
    Rider TG; Jordan KM
    Rheumatology (Oxford); 2010 Jan; 49(1):5-14. PubMed ID: 19808695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained response to anakinra in ankylosing spondylitis.
    Bennett AN; Tan AL; Coates LC; Emery P; Marzo-Ortega H; McGonagle D
    Rheumatology (Oxford); 2008 Feb; 47(2):223-4. PubMed ID: 18073250
    [No Abstract]   [Full Text] [Related]  

  • 37. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs.
    Tran TA; Pariente D; Lecron JC; Delwail A; Taoufik Y; Meinzer U
    Arthritis Rheum; 2011 Dec; 63(12):4031-2. PubMed ID: 21898344
    [No Abstract]   [Full Text] [Related]  

  • 39. Effective treatment of steroid refractory adult-onset Still's disease with anakinra.
    Maier J; Birkenfeld G; Pfirstinger J; Schölmerich J; Fleck M; Brühl H
    J Rheumatol; 2008 May; 35(5):939-41. PubMed ID: 18464320
    [No Abstract]   [Full Text] [Related]  

  • 40. Macrophage activation syndrome treated with anakinra.
    Durand M; Troyanov Y; Laflamme P; Gregoire G
    J Rheumatol; 2010 Apr; 37(4):879-80. PubMed ID: 20360206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.